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TLRs IN HEALTHY TISSUE
Pattern recognition forms the basis of
the innate immune system, allowing it to
maintain systemic homeostasis by reject-
ing harmful molecular structures. Immune
cells as well as epithelial cells located near
the host–environment boundary, express
pattern-recognizing receptors, the activa-
tion of which launches cascades lead-
ing to immune response and apopto-
sis (1, 2). Human toll-like receptors
(TLRs) 1–10, a family of trans-membrane
receptor proteins comprising one type
of pattern-recognizing receptors, partic-
ipate in these immunological processes.
In healthy immune cells and epithelial
cells, TLR 1, 2, 4, 5, 6, and 10 are usu-
ally expressed on the cell surface, whereas
TLR 3, 7, 8, and 9 are mainly expressed
on the surfaces of endosomes, lysosomes,
and endoplasmic reticulum (3). Microbial
molecular structures activating pattern-
recognizing receptors are called pathogen-
associated molecular patterns (PAMPs)
(1, 2). Besides exogenous structures, also
endogenous molecules, released, for exam-
ple, from inflamed or damaged tissues, can
activate pattern-recognizing receptors and
are called danger- or damage-associated
molecular patterns (DAMPs) (4, 5). Lig-
ands binding to TLR lead to the activa-
tion of several intracellular signaling path-
ways, activating, for instance, nuclear tran-
scription factors that initiate host defense
functions via secretion of co-stimulatory
factors and cytokines (6). TLR activation
leads also to regulation of gene expression,
cell proliferation, differentiation, mitosis,
cell-cycle regulation, and apoptosis (7).
TLRs IN ABNORMAL CONDITIONS
In healthy tissues, TLRs participate in the
initiation of inflammatory defense mech-
anisms, but under abnormal conditions
their activation may lead to the process of
inflammation becoming chronic. Chronic
inflammation is a favorable environment
for tumor initiation and progression in
multiple organs, including the cervix,
stomach, colon, and liver (8–11). In sev-
eral pre-malignant and malignant condi-
tions, TLRs have been overexpressed (12–
15). TLRs can activate immunity affect-
ing proteins like nitric oxide synthase 2
and cyclooxygenase 2, leading to increased
malignant potential of cancer cells (12,
16). TLRs can also up-regulate immuno-
suppressive agents like vascular endothelial
growth factor, and transforming growth
factor beta within the tumor microenvi-
ronment and thus modulate immunity.
These modifications can lead to increased
angiogenic and metastatic potential of
tumors (17). The role of TLRs in can-
cer is, however, controversial. Activation
of TLRs can also lead to tumor inhibi-
tion (18–21). The role of TLRs in cancer
is therefore ambiguous, as they can on the
one hand mediate signaling leading to inhi-
bition of apoptosis and disrupted cell pro-
liferation, and on the other hand, activate
immunologic responses against cancer.
Patterns of TLRs expression in terms of
frequencies and their subcellular locations
are different in cancer microenvironment
and in healthy tissue. Here, we discuss the
observations of TLR expression patterns
in normal, pre-malignant, and carcinoma
tissues.
TRANSFORMATION OF TLR
EXPRESSION IN CANCEROUS
PROGRESSION
Under normal circumstances, TLR 2, 4,
and 5 are expressed principally on the
membrane. During the transformation
toward dysplasia, their expression becomes
stronger and more cytoplasmic.
The transforming expression pattern
has been shown, for example, in the sit-
uation of TLR 5 and normal esophageal
epithelium transforming toward cancer. In
non-dysplastic esophageal epithelium,TLR
5 expression is located exclusively in baso-
lateral plasma membrane and basal cyto-
plasm (15). During the progression toward
dysplasia, the polarity of TLR 5 expression
ceases and expression becomes more dif-
fuse. In esophageal adenocarcinoma, the
intensity of TLR 5 staining is weaker, when
compared to that of columnar epithelial
dysplasia, but it follows identical diffuse
staining pattern (15). In oral epithelium,
TLR 5 expression is already cytoplasmic
in healthy tissue but its expression in oral
epithelial cancer has been stronger than in
healthy epithelium (22).
The phenomenon of stronger and more
diffuse TLR expression has appeared also
in other TLR subtypes and cancer types.
Healthy colon mucosa expresses only
www.frontiersin.org December 2014 | Volume 5 | Article 638 | 1
Jouhi et al. TLR expression patterns in carcinogenesis
minor TLR 4 positivity. In colon dyspla-
sia and adenocarcinoma, TLR 4 expression
becomes more evident and is strong and
diffuse both in cytoplasm and on mem-
branes (23). TLR 2, 4, and 5 follow the same
diffuse cytoplasmic pattern in colon adeno-
carcinoma,TLR 2 and 4 in gastric columnar
epithelial dysplasia, and adenocarcinoma,
and TLR 2 and 4 in follicular thyroid
carcinoma (24–26).
In colon and gastric columnar epithe-
lial dysplasia, the level of a TLR antag-
onist, toll-interacting protein (TOLLIP)
decreases, whereas TLR expression trans-
forms toward being more diffuse and
cytoplasmic. The normal TOLLIP path-
way leads to the degradation of excess
TLRs. Disruption of the TOLLIP pathway
results in excess and altered TLR expression
(24, 25).
When DAMPs are bound to plasma
membrane or as the cell loses its plasma
membrane integrity, and they are released
to extracellular matrix, the immune
response is initiated (27, 28). DAMPs are
able to interact with the immune system to
cause tumor suppression, but on the other
hand, they can also contribute to cancer
progression (29).
DAMPs are confined to the cytosol and
nucleus of healthy cells (28). In cancer cells,
however, they can be overexpressed, and
their intracellular localization can become
altered. For example, in cancer, the nor-
mally nuclear DAMP-molecule HMGB1
is overexpressed in cytoplasm (30, 31).
TLRs 2, 4, and 9 are target receptors for
HMGB1 and their activation can launch
cascades leading, for instance, to induc-
tion of pro-inflammatory cytokines, pro-
motion of angiogenesis, and stimulation
of cell migration via downstream intra-
cellular pathways (32). Previously, TLRs
that are overexpressed in cytoplasm are
suggested to function as a reserve for
greater redistribution to the plasma mem-
brane, where they are activated by their
extracellular ligands, such as bacteria (24,
25). We could, however, hypothesize that
TLRs that are overexpressed and relocated
to the cytoplasm in cancer might also
be activated in the cytoplasm by their
DAMP-ligands, which are equally over-
expressed and relocated in to the cyto-
plasm. This kind of abnormal and uninter-
rupted intracellular TLR activation could
lead to tumor progression in addition to
normal inflammatory cascades, although
the role of cytoplasmic TLRs needs further
study.
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